National Childhood Cancer Foundation.

IF 6.3 2区医学 Q1 ONCOLOGY Neoplasia Pub Date : 1999-09-15 DOI:10.1038/SJ.NEO.7900031

M. Brucker

引用次数: 4

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

国家儿童癌症基金会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neoplasia ONCOLOGY-

自引率

2.10%

发文量

期刊介绍： Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.

期刊最新文献

Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity. Corrigendum to "Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+-LSL-KrasG12D/+ Mice" [Neoplasia, Volume 14, Issue 9 (2012) 778-787]. Engineering and characterization of Hu3A4: A novel humanized antibody with potential as a therapeutic agent against myeloid lineage leukemias. Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis. Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer.